Alkermes plc (ALKS)
ALKS Price and Sentiment
ALKS Latest news
Alkermes Announces First Subject Dosed in Phase 1 Study of ALKS 1140 for the Treatment of Neurodegenerative and Neurological Disorders2021-11-11 07:00
DUBLIN, Nov. 11, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced dosing of the first subject in a phase 1 study evaluating the safety and tolerability of ALKS 1140 in healthy adults. ALKS 1140 is a novel, investigational CoREST-selective (co-repressor of repressor element-1 silencing transcription factor) HDAC (histone deacetylase) inhibitor candidate for the treatment of neurodegenerative and neurological disorders.
Alkermes (ALKS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
DUBLIN, Nov. 9, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Stifel Virtual Healthcare Conference on Tuesday, Nov. 16, 2021 at 9:20 a.m. ET (2:20 p.m.
Johnson & Johnson partly ended two licensing agreements with the company.
DUBLIN, Nov. 8, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it received notices of partial termination (the "Notices") in respect of two license agreements with Janssen Pharmaceutica N.V. ("Janssen"), a subsidiary of Johnson & Johnson and, under these agreements, a licensee and recipient of Alkermes' nanoparticulate formulation technology, known as NanoCrystal® technology.
Alkermes to Present Data on Nemvaleukin Alfa at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting2021-11-03 07:00
DUBLIN, Nov. 3, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present a poster related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting, taking place Nov. 10-14, 2021. The poster will include data from the ION-01 study, a phase 2 trial evaluating intravenous nemvaleukin in combination with pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma that had previously progressed on an anti-PD-(L)1 therapy.
It looks like we're on the back end of the Covid pandemic, so it's a good time to look at healthcare stocks that have a big future. The post 7 A-Rated Healthcare Stocks to Buy for the Long Haul appeared first on InvestorPlace.
Alkermes' (ALKS) earnings in the third quarter of 2021 beat estimates while revenues miss the same. The company reiterates financial guidance for the ongoing year.
Alkermes plc. (ALKS) CEO Richard Pops on Q3 2021 Results - Earnings Call Transcript
Alkermes plc (NASDAQ: ALKS) posted Q3 sales of $294.1 million, up 11% Y/Y, missing the consensus of $301.36 million. Vivitrol sales increased 11% to $88.8 million, and Aristada sales increased 10% to $68.9 million.